Novartis said on Thursday its Fabhalta drug was shown to meaningfully slow the progression of a rare type of kidney disease ...

The drug’s accelerated approval was based on the intermediate endpoint of improvement in knee extensor muscle strength. The ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

(Reuters) -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based ...

Having already established a commercial infrastructure for its oral hereditary angioedema (HAE) drug Orladeyo and eager to ...

But recently, scientists took inspiration for such a super drug from a quiet corner of the medical world: The small subset of ...

Working with agency partner DCX Growth Accelerator, GeneDX takes direct aim at the issue of underdiagnosis of pediatric rare diseases.

Bristol Myers Squibb's acquisition of Orbital Therapeutics includes OTX-201, a next-gen CAR T-cell therapy, and a proprietary ...

Nine-year-old Emma D. of Fishers, Indiana, received national recognition for her courage this week at the American Kidney ...

MIT has launched the Rare Brain Disorders Nexus (RareNet) to enhance research on rare brain conditions, founded with a ...

While the M&A emphasis is currently on life sciences, a business unit which sells products used in R&D and manufacturing ...